FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. - Wikidata - awgldk - TriplyDB

FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

http://www.wikidata.org/entity/Q35914501

about

Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients Antiangiogenic therapy of brain tumors: the role of bevacizumab.Imaging biomarkers for antiangiogenic therapy in malignant gliomas.The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.A comparison of PET imaging agents for the assessment of therapy efficacy in a rodent model of glioma 18 F-FDG PET standard uptake values of the normal pons in children: establishing a reference value for diffuse intrinsic pontine glioma.Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients.Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis.Quantitative Imaging Biomarkers for Risk Stratification of Patients with Recurrent Glioblastoma Treated with Bevacizumab.Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.Differentiation of tumor sensitivity to photodynamic therapy and early evaluation of treatment effect by nuclear medicine techniques.Relationship of computed tomography perfusion and positron emission tomography to tumour progression in malignant glioma.Multiparametric MRI and [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging Is a Potential Prognostic Imaging Biomarker in Recurrent Glioblastoma.18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.Evaluation of therapeutic effect of tumor-targeted therapy.The Added Prognostic Value of Metabolic Tumor Size on FDG-PET at First Suspected Recurrence of Glioblastoma Multiforme.Magnetic Resonance Spectroscopy, Positron Emission Tomography and Radiogenomics-Relevance to Glioma.Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas

P2860

Q26853308-020BA691-3837-4C0F-B51E-FEB317ABA334 Q30737224-3026D130-3F9D-40F4-8924-D9D8C7AC90CC Q30764736-909FC193-B0F0-48EE-B3BF-9354183047B8 Q34293163-465B10F0-1572-429D-9D40-2CECEFBFE7F9 Q34348544-692FA242-C02A-4746-84A7-713474CB1EF3 Q35895174-F0C46560-8549-4C55-A4A1-05914FE061E6 Q36076814-C9F4B2DF-EE86-4A5A-A402-54E0B61E3546 Q37201450-52B67725-3A1E-41CD-8756-7BF17B86C8C1 Q37542423-4F81DFF6-8369-48F9-AAA5-243127401CF1 Q37641220-8C5D9FA8-C338-4C63-8DE8-12C2EE8EBE87 Q38068203-F27F6132-DF6F-4737-90CD-D1B15E0F0871 Q38561073-1A92D523-1875-4DBB-840E-EC20D1124A2E Q38789124-AABF65C3-82C7-4CA1-9A9D-33FDA82A616A Q38815396-839CD8D6-6CFA-4FAD-890E-F746ABAC1BDE Q39153116-78188C9C-FDD2-4B49-8979-FE507439DC29 Q39260129-2FFC4F91-37E2-4305-B19A-76E561057454 Q41462863-C7082AF5-E50D-403C-B35A-5A1B81F40A0E Q41877778-DC2AEA6E-5A6D-40AF-8DD8-A8D2FE20F5C6 Q41962463-5AC809C7-FA93-420F-861C-47B0949837AE Q47281917-51149E6F-B7DB-4640-83E1-4D3F48003335 Q49829513-7129C2E3-4E13-4F65-A0B2-588EA2EF37FD Q57177114-C9A35568-E8F0-4EA5-80BC-1D1E7DF7573D

P2860

FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

http://www.wikidata.org/entity/Q35914501

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

FDG-PET predicts survival in r ...... th bevacizumab and irinotecan.

@ast

FDG-PET predicts survival in r ...... th bevacizumab and irinotecan.

@en

type

label

FDG-PET predicts survival in r ...... th bevacizumab and irinotecan.

@ast

FDG-PET predicts survival in r ...... th bevacizumab and irinotecan.

@en

prefLabel

FDG-PET predicts survival in r ...... th bevacizumab and irinotecan.

@ast

FDG-PET predicts survival in r ...... th bevacizumab and irinotecan.

@en

P1433

Q35914501-C081C613-7D9C-4AD9-9C2B-E3145809421D

P1476

Q35914501-50B8E0D9-56C1-40FE-87E1-BD904B89B89F

P2093

Q35914501-04F25424-0FB9-49B8-880E-3FC8CA73D5C3

Q35914501-3FC305BD-E729-4887-987C-75C2E76FE1F3

Q35914501-85DB8B1E-9D27-41FB-834A-820FB19ACEE5

Q35914501-CC435C02-CEB9-49CC-8D7A-3D3377A9C935

Q35914501-D3159C30-7F35-4B2E-A139-E46F3C72FB1B

Q35914501-D632522B-6E5A-49D4-A82D-86AAAFC46CB2

Q35914501-F8BE39CF-DC57-4530-8917-ED5FF5D82144

Q35914501-FADCCD9C-DAD3-4701-9CCF-A079B416F6C5

P2860

Q35914501-00CB0AFD-5537-4068-9F65-0CFB38E447E3

Q35914501-0384666B-F887-4FAA-A0D2-1A8FF7C74BFD

Q35914501-05C5DD51-BABF-4DAB-9426-E7AF6D2324D0

Q35914501-0A672E9F-17D1-4DBA-AE19-F3800DB2F663

Q35914501-0D9A63B6-3A20-4B03-8641-C21EFF33EA9B

Q35914501-0DB4424D-BEAB-4A89-8F2A-31E70D37DB9B

Q35914501-0E75FC17-87A3-4AD9-8CEE-54328AA261C9

Q35914501-1A488E34-D43A-41D3-82DE-C0D33C4B7FE1

Q35914501-2200092B-85DA-444F-B264-92EAEB7EB33D

Q35914501-28400A35-A072-4891-B193-D3D1AE9B533A

P304

Q35914501-7B63E683-E0B3-471C-9571-53F5B88090A1

P31

Q35914501-A807D809-CD80-4137-9254-33A67C30AB63

P356

Q35914501-E4B64FB3-B09E-4F23-9642-B8CE617EABB7

P433

Q35914501-9B985D9C-94C6-435A-A4C9-5EAF01B0355A

P478

Q35914501-0C4B906F-D1F2-4865-8F86-CAF5BBBAF806

P50

Q35914501-AA1BC154-4C94-4B1A-A841-D140941C8792

Q35914501-C0BA6E31-7D57-46DA-B3CC-D35D0DEB9274

P577

Q35914501-F663FD0C-7181-461B-9DA2-7E1036A47F34

P5875

Q35914501-9BA597D8-EE0C-43E9-8ED0-E6A9B30D552E

P698

Q35914501-79230645-34B2-423E-90FE-A38775BE5E6D

P921

Q35914501-BE5F5EAE-51C4-4F1E-8D45-4C280FEDDF82

P932

Q35914501-07A4F091-0D91-41DB-ACFA-1012A337E8D6

P356

P1433

P1476

FDG-PET predicts survival in r ...... th bevacizumab and irinotecan.

@en

P2093

Cécile Colavolpe

http://www.w3.org/2001/XMLSchema#string

Céline Bequet-Boucard

http://www.w3.org/2001/XMLSchema#string

Emeline Tabouret

http://www.w3.org/2001/XMLSchema#string

Eric Guedj

http://www.w3.org/2001/XMLSchema#string

Maryline Barrie

http://www.w3.org/2001/XMLSchema#string

Olivier Chinot

http://www.w3.org/2001/XMLSchema#string

Olivier Mundler

http://www.w3.org/2001/XMLSchema#string

Philippe Metellus

http://www.w3.org/2001/XMLSchema#string

P2860

The 2007 WHO classification of tumours of the central nervous system

On the Origin of Cancer Cells

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Primary brain tumours in adults.

Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.

Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Anaplastic astrocytoma in adults.

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.

Imaging angiogenesis: applications and potential for drug development.

P304

649-657

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOS012

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Dominique Figarella-Branger

P577

2012-02-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221874767

http://www.w3.org/2001/XMLSchema#string

P698

22379188

http://www.w3.org/2001/XMLSchema#string

P921

P932

3337300

http://www.w3.org/2001/XMLSchema#string